Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study

The influence of HBV infection status on such a risk has never been estimated accurately; the results of published studies may have been influenced by concomitant hepatotoxic pharmacotherapy, underlying disease, and other patient characteristics. [...]this study reflects the precise risk of ALT elevation in HBV-infected patients because most were prescribed anti-TNF agents before formal risk management guidelines were issued in Taiwan and, therefore, received no prior antiviral prophylaxis [28]. Furthermore, it is likely that studies from different countries used different treatment strategies... Mehr ...